Athira Pharma's fosgonimeton (ATH-1017) targets the same HGF/c-Met program but is structurally distinct (sources conflict on whether it is a prodrug of Dihexa or a separate molecule)
A study looking for patterns about types of authors involved in retractions (all reasons), suggested that Early Career Researchers were particularly likely to be involved in retractions (Fanelli, Costas & Larivire, 2015), although the exact reason why remains obscure
What science exists for GHK-Cu is all rather positive (a 2018 analysis of the science concluded the peptides actions appear to be health positive, saying it boosts collagen, improves tissue repair and has powerful cell-protective actions, including multiple anti-cancer and anti-inflammatory actions)
Early studies on Gly-His-Lys (GHK), first discovered in human plasma in the 1970s, demonstrated their ability to modulate gene expression, stimulate collagen synthesis, and accelerate wound healing, sparking broad interest in these bioactive molecules [23]